CACNA1D
MOLECULAR TARGETcalcium voltage-gated channel subunit alpha1 D
CACNA1D (calcium voltage-gated channel subunit alpha1 D) is targeted by 7 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).
Compounds Targeting CACNA1D
Ranked by bioassay confidence score (PubChem active assay count × evidence quality).
| # | Compound | Confidence | Active Assays |
|---|---|---|---|
| 1 | nifedipine | 5.34 | 208 |
| 2 | Nitrendipine | 1.95 | 6 |
| 3 | Nisoldipine | 1.10 | 2 |
| 4 | Amlodipine | 0.69 | 1 |
| 5 | Duloxetine Hydrochloride | 0.69 | 1 |
| 6 | Astemizole Antihistamine drug now withdrawn from | 0.69 | 1 |
| 7 | Quinidine | 0.69 | 1 |
About CACNA1D as a Drug Target
CACNA1D (calcium voltage-gated channel subunit alpha1 D) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 7 compounds with documented CACNA1D interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.
CACNA1D inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.